Company Profile
Xeris Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- XERS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
16.62 USD (-2.18%)
Close
Last updated: November 19, 2026
1.04B USD
Market cap
Why the stock is moving
As of Nov 19, 2026, XERS closed down 2.18% at $16.62. No new same-company headline was identified in the current news window.
Company overview
Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
Hypothyroidism Pipeline
XP-8121 is an investigational once-weekly subcutaneous levothyroxine formulation for patients with hypothyroidism. The pivotal Cornerstone program is designed to compare it with daily oral replacement therapy.
Formulation Platforms
XeriSol and XeriJect are proprietary technologies for creating ready-to-use liquid or suspension formulations of molecules that are difficult to deliver. They support both internal products and partnered programs.
Future catalysts
- Initiation of the pivotal Phase 3 Cornerstone study of XP-8121 by year-end 2026.
- Topline Cornerstone results in late 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals (XERS) most recently closed at 16.62 USD, a -2.18% move versus the previous session.
What is the market cap of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals currently has a market capitalization of 1.04B USD on BioPharmSignal.
What does Xeris Pharmaceuticals do?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use...
On which exchange is XERS stock listed?
Xeris Pharmaceuticals (XERS) is associated with NASDAQ, United States, Biopharma.
What is XP-8121?
Initiation of the pivotal Phase 3 Cornerstone study of XP-8121 by year-end 2026.
Which conditions is Xeris Pharmaceuticals targeting with XP-8121?
Xeris Pharmaceuticals is associated with neurology based on its company overview and current catalyst commentary.
How does Xeris Pharmaceuticals describe recent progress with XP-8121?
Initiation of the pivotal Phase 3 Cornerstone study of XP-8121 by year-end 2026.
What is Specialty?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
